Pharmacodynamic effects of a new antihypertensive drug, Catapres (ST-155).
D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D002319:Cardiovascular System / Q000187:drug effects*; D002752:Chlorthalidone / Q000008:administration & dosage; D004395:Dye Dilution Technique; D005919:Glomerular Filtration Rate; D006145:Guanethidine / Q000494:pharmacology; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology*; D007668:Kidney / Q000098:blood supply*; D008750:Methyldopa / Q000494:pharmacology; D010293:Pargyline / Q000494:pharmacology; D011187:Posture; D012965:Sodium Chloride / Q000652:urine; D013997:Time Factors; D014655:Vascular Resistance / Q000187:drug effects
D000959:Antihypertensive Agents; D007093:Imidazoles; D012965:Sodium Chloride; D008750:Methyldopa; D010293:Pargyline; D002752:Chlorthalidone; D006145:Guanethidine